Each tablet contains:
Terazosin (as hydrochloride) 2 or 5 mg
Treatment of hypertension (HTN)and symptomatic benign prostatic hyperplasia (BPH).
Hypersensitivity to any of the product’s ingredients.
Precaution & warnings:
May cause marked lowering of BP especially postural hypotension and syncope with the 1st dose or 1st few days of therapy; similar effect may be anticipated if therapy is discontinued for several days and then restarted.
May impair physical/mental abilities.
Examine patients with BPH to rule out prostate cancer prior to initiation of therapy.
Priapism (rare) reported. Monitor for signs/symptoms of priapism.
Intraoperative floppy iris syndrome observed during cataract surgery.
Decreases in Hct, Hgb, WBC, total protein and albumin reported, possibly due to hemodilution. Monitor Hct, Hgb, WBC, total protein/albumin, and BP periodically.
Safety and efficacy have not been established for pediatrics.
Pregnancy & Breastfeeding:
Category C, caution in nursing.
Dosage and administration:
“ If discontinued for several days or longer, restart using the initial dosing regimen. “
Initial: 1mg at bed time.
Maintenance: 1-5mg once a day. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered. Doses over 20 mg do not appear to provide further blood pressure effect.
Max: 40 mg/day.
Initial: 1mg every night at bed time.
Titrate: Increase stepwise to 2mg, 5mg, or 10mg once a day to achieve the desired improvement of symptoms and/or flow rates (doses of 10 mg/day are generally required for an adequate response).
Maintenance: 10 mg/day. Assess clinical response after 4-6 weeks.
Max: 20 mg/day.
Asthenia, postural hypotension, headache, dizziness, dyspnea, nasal congestion, somnolence, palpitations, nausea, peripheral edema, pain in extremities.
Caution with other antihypertensive agents , especially verapamil.
When using terazosin and other antihypertensive agents concomitantly, dosage reduction and retitration of either agent may be necessary.
Increased levels with captopril may happen.
Hypotension reported with PDE-5 inhibitors.
Store below 30°C. Protect from light and moisture.